Last Updated: November 16, 2026

Investigational Drug Information for Merestinib

« Back to Dashboard


What is the development status for investigational drug Merestinib?

Merestinib is an investigational drug.

There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on November 11th 2016.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Jacqueline Garcia, MD.

Recent Clinical Trials for Merestinib
TitleSponsorPhase
Merestinib on Bone Metastases in Subjects With Breast CancerEli Lilly and CompanyPhase 1
Merestinib on Bone Metastases in Subjects With Breast CancerUniversity of UtahPhase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaEli Lilly and CompanyPhase 1

See all Merestinib clinical trials

Clinical Trial Summary for Merestinib

Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib

See all Merestinib clinical trials

Merestinib Development Update and Market Projection

Last updated: November 13, 2026

Merestinib, also known as LY2801653, is an investigational oral multikinase inhibitor developed by Eli Lilly. It inhibits MET, AXL, MERTK, ROS1, and other kinases implicated in tumor growth, invasion, and resistance. Clinical development reached early- and mid-stage oncology trials, but merestinib has not obtained FDA approval and has no commercial revenue. The current base-case market projection is therefore $0 unless Lilly or another sponsor restarts development.

What is the current development status of merestinib?

Merestinib remains an investigational oncology compound with no publicly established late-stage registration program. Its development history includes Phase 1 and Phase 2 studies in advanced solid tumors, including colorectal cancer, gastric cancer, hepatocellular carcinoma, non-small-cell lung cancer, and other MET- or kinase-driven malignancies.

Item Status
Generic name Merestinib
Development code LY2801653
Originator Eli Lilly and Company
Drug class Oral small-molecule multikinase inhibitor
Principal targets MET, AXL, MERTK, ROS1 and related kinases
Route Oral
FDA approval None identified
U.S. commercial sales None
Orange Book listing None
Biosimilar relevance Not applicable
Current development posture No established active registration program

Merestinib was designed as a broad-spectrum kinase inhibitor rather than a highly selective MET inhibitor. Its development rationale centered on blocking MET signaling while also addressing AXL, MERTK, and other pathways associated with tumor progression and acquired drug resistance. Publicly reported clinical work did not establish a validated pivotal indication.

Which cancers were studied with merestinib?

Merestinib was studied across tumor types where MET signaling or related receptor tyrosine kinases were considered clinically relevant.

Colorectal cancer

Merestinib was evaluated in advanced colorectal cancer, including studies involving patients whose disease had progressed after standard treatment. The rationale included potential inhibition of MET-driven signaling and resistance mechanisms. Clinical activity was not sufficient to produce an established approval pathway.

Gastric and gastroesophageal cancer

MET signaling has been associated with aggressive gastric and gastroesophageal tumors. Merestinib was investigated in this setting as a systemic kinase inhibitor. The program did not advance to a publicly recognized Phase 3 registration trial.

Hepatocellular carcinoma

MET, AXL, and related pathways have been studied as drivers of hepatocellular carcinoma progression. Merestinib entered clinical evaluation in liver cancer and other solid tumors, but no regulatory filing for hepatocellular carcinoma has been disclosed.

Non-small-cell lung cancer

Merestinib was considered for MET- and ROS1-linked disease biology. Its multikinase profile distinguished it from selective MET inhibitors such as capmatinib and tepotinib, and from selective ROS1 inhibitors such as crizotinib and entrectinib. The broader target profile did not produce a commercially established lung-cancer indication.

What clinical evidence supports merestinib?

The available evidence is primarily early-stage and exploratory. Phase 1 work assessed safety, tolerability, pharmacokinetics, dose selection, and preliminary antitumor activity in patients with advanced solid tumors. Later studies explored selected tumor types and combinations.

Reported development risks included:

  • A broad target profile that increased the potential for off-target toxicity.
  • Difficulty identifying a biomarker-defined population with a sufficiently strong response rate.
  • Competition from more selective kinase inhibitors.
  • A crowded oncology market with approved therapies and rapidly advancing targeted agents.
  • The need to demonstrate clinical value beyond MET-selective drugs and immune checkpoint inhibitors.

Merestinib’s potential therapeutic value depended on showing that simultaneous inhibition of MET and additional kinases improved outcomes over more selective or better-established alternatives. Public clinical development did not demonstrate that advantage.

When did merestinib lose exclusivity?

Merestinib has not reached regulatory exclusivity because it has not been approved by the FDA. The relevant commercial issue is development discontinuation or inactivity rather than loss of market exclusivity.

The product has no:

  • New chemical entity exclusivity period.
  • FDA orphan-drug exclusivity period.
  • Pediatric exclusivity period.
  • Approved labeling-based market protection.
  • Orange Book-listed patents supporting an approved product.

Patent rights may still exist in individual jurisdictions, including composition-of-matter, formulation, crystalline-form, therapeutic-use, or manufacturing patents. Those rights do not create an active pharmaceutical market without an approved product.

What patents protect merestinib?

Public records associate merestinib with Eli Lilly patent filings covering kinase-inhibitor compounds, pharmaceutical compositions, and therapeutic applications. The precise surviving patent estate depends on jurisdiction, terminal disclaimers, patent-term adjustment, maintenance-fee status, and claim scope.

A definitive patent-expiration table cannot be constructed from the drug name alone because merestinib was developed under the LY2801653 code and may appear in patent documents as one compound among broader Markush structures. Patent families may also identify the compound through chemical names rather than the development code.

The key patent categories are:

Patent category Commercial relevance
Composition of matter Typically the strongest protection if claims specifically cover merestinib
Genus or Markush claims Scope depends on claim construction and invalidity risk
Pharmaceutical composition May protect dosage forms or excipient combinations
Method of treatment May cover MET-driven or particular oncology indications
Combination therapy May cover use with chemotherapy, immunotherapy, or targeted agents
Manufacturing process Can create technical barriers but usually does not prevent all alternative synthesis routes

Because merestinib is not approved, there is no Orange Book patent-listing framework applicable to an approved product. No public U.S. Paragraph IV litigation pathway has been established for merestinib.

What is the FDA regulatory status of merestinib?

Merestinib is not an FDA-approved drug. It does not have an FDA-approved indication, label, dosage recommendation, safety warning, or regulatory exclusivity period.

The development record is consistent with an investigational new drug program that progressed through early clinical testing but did not produce a publicly disclosed New Drug Application approval. Merestinib is therefore not available as a lawful commercial prescription product in the United States.

Which companies are challenging merestinib?

No publicly established generic or biosimilar challenge has been identified.

Paragraph IV litigation is unlikely to arise before approval because an abbreviated new drug application requires a reference-listed drug. Merestinib has no FDA reference-listed drug and no Orange Book entry. Biosimilar competition is also irrelevant because merestinib is a small-molecule drug, not a biologic.

The relevant competitive pressure came from other oncology developers rather than generic manufacturers.

Competitive drugs and companies

Drug Company or originator Position relative to merestinib
Capmatinib Novartis Selective MET inhibitor with FDA approval for MET exon 14 skipping NSCLC
Tepotinib EMD Serono/Merck KGaA Selective MET inhibitor with FDA approval for MET exon 14 skipping NSCLC
Crizotinib Pfizer Multi-targeted ALK, ROS1, and MET inhibitor with approved indications
Entrectinib Genentech/Roche TRK and ROS1 inhibitor
Cabozantinib Exelixis Broad kinase inhibitor with established renal, liver, and thyroid cancer indications
Savolitinib AstraZeneca/HutchMed Selective MET inhibitor developed in lung cancer
Volitinib HutchMed Selective MET inhibitor development program

Merestinib’s broad activity created a differentiation opportunity, but it also exposed the program to direct comparison with selective agents that had clearer biomarker strategies and regulatory endpoints.

How strong is the merestinib patent estate?

The commercial strength of the merestinib estate is limited by the absence of an approved product and the lack of a publicly visible late-stage program.

Strengths

  • Early composition-of-matter filings may provide the strongest potential protection.
  • Broad kinase target coverage could support multiple method-of-use positions.
  • Combination-treatment claims may have relevance if supported by clinical data.
  • Lilly’s original ownership provides a clear historical sponsor and development record.

Weaknesses

  • No approved indication converts patent rights into a protected market.
  • Clinical validation of a specific biomarker population remains limited.
  • Broad kinase claims may face written-description, enablement, obviousness, or claim-construction challenges.
  • Selective MET competitors reduce the commercial value of a broad multikinase mechanism.
  • A dormant or discontinued program reduces the practical value of remaining patent life.

The patent estate should therefore be treated as an option on a redevelopment program, not as current commercial protection.

What formulation and manufacturing rights protect merestinib?

Merestinib was developed as an oral small molecule. Public clinical use indicates an orally administered formulation, but no FDA-approved commercial formulation exists.

Potential formulation protection could include:

  • Solid oral dosage forms.
  • Specific salt or crystalline forms.
  • Particle-size or dissolution specifications.
  • Pharmaceutical compositions with selected excipients.
  • Process claims for producing the active pharmaceutical ingredient.

Manufacturing patents would matter most if the compound has difficult stereochemical, crystallization, purification, or scale-up requirements. No public evidence establishes that manufacturing complexity is currently a material barrier to a third-party redevelopment program.

What licensing deals involve merestinib?

Merestinib was developed by Eli Lilly. No major publicly disclosed out-licensing transaction has established a new commercial sponsor, regional licensee, or co-development partner for the compound.

The absence of a visible licensing transaction reduces the probability of near-term clinical reactivation. A future transaction would likely require a new sponsor to obtain rights, repeat biomarker work, define a differentiated indication, and fund a new clinical strategy.

What is the market projection for merestinib?

The current commercial forecast is zero because merestinib has no approval, no marketed formulation, and no recognized revenue stream.

Forecast element Current assessment
Current sales $0
FDA launch probability under the inactive-program base case 0% near term
Generic erosion risk None before approval
Biosimilar erosion risk Not applicable
Near-term market size $0
Redevelopment value Contingent on new clinical and regulatory investment
Primary value driver Identification of a biomarker-defined, underserved indication

A redevelopment scenario could target MET-amplified or MET-overexpressing tumors, but that would require new clinical evidence. The product would compete with approved MET inhibitors, broad kinase inhibitors, antibody-drug conjugates, immunotherapies, and emerging combination regimens.

A credible revenue forecast cannot be based on historical trial enrollment or theoretical target-market size. The commercial model would require:

  1. A new sponsor or Lilly reactivation.
  2. A defined molecular selection strategy.
  3. Dose and safety confirmation.
  4. A registrational indication.
  5. Demonstrated differentiation from capmatinib, tepotinib, crizotinib, and cabozantinib.
  6. Regulatory approval and reimbursement access.

Without those milestones, any multibillion-dollar market estimate would be speculative.

What generic launch risks exist for merestinib?

There is no conventional generic-launch risk because merestinib has not become an approved reference product. If development resumed and approval followed, launch risk would depend on:

  • Surviving composition-of-matter patents.
  • Patent-term restoration.
  • Method-of-use patents.
  • Approved formulation claims.
  • Whether the label contains carve-out indications.
  • Paragraph IV challenges.
  • The size of the treated biomarker population.
  • Manufacturing complexity and API availability.

The earliest practical competition would likely come from other branded kinase therapies rather than generic merestinib.

What is the geographic coverage of merestinib rights?

Lilly’s historical development program indicates an international strategy, with clinical research conducted under global regulatory frameworks. Patent coverage may have existed in the United States, Europe, Japan, China, and other major pharmaceutical markets.

Geographic commercial value is currently limited because there is no approved product in any major market. Patent status should be checked separately by jurisdiction because grant, lapse, expiration, and claim scope can vary significantly.

Key Takeaways

  • Merestinib, or LY2801653, is an Eli Lilly investigational oral multikinase inhibitor.
  • Its main targets include MET, AXL, MERTK, and ROS1.
  • Clinical development reached early and mid-stage oncology studies but did not produce an approved indication.
  • Merestinib has no FDA approval, Orange Book listing, commercial revenue, or biosimilar pathway.
  • No established Paragraph IV litigation or generic challenge exists.
  • Patent rights may remain in selected jurisdictions, but their commercial value is constrained by the absence of an approved product.
  • The current market forecast is $0.
  • Any redevelopment value depends on a new biomarker strategy and differentiation from approved selective MET and other kinase inhibitors.
  • The most plausible future commercial path would be a licensed or revived program focused on a narrowly defined, treatment-resistant, MET-driven population.

FAQs

Is merestinib still in clinical trials?

No active registration program has been publicly established. Historical studies evaluated merestinib in advanced solid tumors and selected gastrointestinal, liver, colorectal, and lung cancers.

Is merestinib approved for cancer treatment?

No. Merestinib has no FDA-approved indication and is not an approved commercial prescription drug.

Does merestinib compete with capmatinib?

Mechanistically, yes. Both affect MET signaling, but capmatinib is a selective MET inhibitor with an approved indication for MET exon 14 skipping non-small-cell lung cancer, while merestinib remains investigational.

Can a generic company launch merestinib?

Not currently through the standard abbreviated new drug application pathway because merestinib has no FDA reference-listed drug. A future generic pathway would arise only after an approved reference product existed.

What would make merestinib commercially viable?

A new sponsor would need to identify a biomarker-selected population in which merestinib’s multikinase activity produces better clinical outcomes than selective MET inhibitors and other approved targeted therapies.

References

  1. ClinicalTrials.gov. (n.d.). Merestinib and LY2801653 clinical study records. U.S. National Library of Medicine. https://clinicaltrials.gov/

  2. Eli Lilly and Company. (2014-2024). Annual reports and regulatory filings. https://investor.l Lilly.com/

  3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. National Cancer Institute. (n.d.). Merestinib. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/merestinib

  5. PubChem. (n.d.). Merestinib. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/

  6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.